Ken Griffin Biomarin Pharmaceutical Inc Transaction History
Citadel Advisors LLC
- $509 Billion
- Q1 2025
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Citadel Advisors LLC holds 154,400 shares of BMRN stock, worth $9.01 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
154,400
Previous 95,400
61.84%
Holding current value
$9.01 Million
Previous $6.27 Million
74.07%
% of portfolio
0.0%
Previous 0.0%
Shares
31 transactions
Others Institutions Holding BMRN
# of Institutions
662Shares Held
185MCall Options Held
1.24MPut Options Held
957K-
Black Rock Inc. New York, NY22.7MShares$1.33 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA19MShares$1.11 Billion0.03% of portfolio
-
Primecap Management CO Pasadena, CA17.8MShares$1.04 Billion1.06% of portfolio
-
Dodge & Cox San Francisco, CA15MShares$873 Million0.65% of portfolio
-
Viking Global Investors LP10.8MShares$630 Million2.55% of portfolio
About BIOMARIN PHARMACEUTICAL INC
- Ticker BMRN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,824,000
- Market Cap $10.8B
- Description
- BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...